Key Takeaways
- PSA (prostate-specific antigen) is a protein produced by the prostate gland, not a direct cancer marker.
- Elevated PSA levels have multiple causes beyond cancer, including benign enlargement and inflammation.
- Major medical organizations recommend shared decision-making rather than universal routine PSA screening.
- Men at higher risk — including Black men and those with a family history — should discuss earlier screening with their doctor.
- A single PSA number rarely tells the whole story; trends over time and additional tests matter.
What the PSA Test Actually Measures
Prostate-specific antigen (PSA) is a protein produced by cells in the prostate gland. A PSA test is a blood draw that measures the concentration of this protein. The test is straightforward; interpreting the result is not.
PSA is not a cancer-specific molecule. The prostate produces it regardless of whether cancer is present. Anything that irritates, enlarges, or inflames the prostate — including benign prostatic hyperplasia (BPH), prostatitis, vigorous exercise, or even recent sexual activity — can raise PSA levels. Understanding this distinction is the foundation of an informed conversation about your results.
PSA is measured in nanograms per milliliter (ng/mL). Historically, a threshold of 4.0 ng/mL was used as a general reference point, but clinicians today consider a range of factors: a man's age, prostate volume, rate of PSA change over time (called PSA velocity), and the ratio of free-to-total PSA. No single cutoff definitively separates benign from malignant conditions. For a broader look at how preventive tests work, see our guide to preventive screenings.
Myth
A high PSA result means you have prostate cancer.
Fact
An elevated PSA can result from several non-cancerous conditions; it is a signal that warrants follow-up, not a diagnosis.
Benign prostatic hyperplasia (BPH) — a non-cancerous enlargement of the prostate that affects most men over 50 — is among the most common reasons for a raised PSA. Prostatitis (prostate inflammation or infection) and even recent physical activity that places pressure on the pelvic region can temporarily increase levels. Studies have found that roughly two-thirds of men with elevated PSA who undergo biopsy do not have cancer. A high result opens a conversation with your doctor; it is not a verdict.
Myth
A normal PSA result means you definitely don't have prostate cancer.
Fact
Prostate cancer can exist in men whose PSA falls within the conventional normal range.
Research, including the Prostate Cancer Prevention Trial, demonstrated that a meaningful proportion of men with PSA levels below 4.0 ng/mL harbored detectable prostate cancer on biopsy. PSA is a useful screening tool, but it has limitations in both directions — it can be falsely reassuring as well as falsely alarming. This is one reason clinical guidelines emphasize ongoing dialogue rather than single-threshold decision-making.
Myth
All prostate cancers detected by PSA testing need immediate aggressive treatment.
Fact
Many PSA-detected prostate cancers are slow-growing and may be safely managed through active surveillance rather than immediate intervention.
Prostate cancer spans a wide spectrum of aggressiveness. Low-grade, localized tumors often grow so slowly that they may never cause symptoms or affect life expectancy. Active surveillance — a structured monitoring protocol involving regular PSA tests, imaging, and periodic biopsies — is a clinically accepted approach for appropriate candidates. The core concern driving screening debates is overtreatment: surgery and radiation carry real risks, including incontinence and erectile dysfunction, that may outweigh the benefit for cancers unlikely to progress.
Myth
PSA testing is recommended for all men over 50 as a routine annual screen.
Fact
Major clinical bodies recommend individualized, shared decision-making rather than universal annual PSA screening.
The U.S. Preventive Services Task Force, American Cancer Society, and American Urological Association all moved away from blanket annual screening recommendations following evidence that population-wide testing led to significant overdiagnosis and overtreatment without a clear survival benefit at the population level. Current guidance centers on informed discussions between patient and clinician, factoring in age, risk profile, values, and preferences. Prostate health is one of several preventive areas men commonly delay — a conversation with your doctor can clarify what applies to you.
Myth
The PSA test is the only tool doctors use to evaluate prostate health.
Fact
PSA is one component of prostate evaluation; clinicians may also use digital rectal examination, imaging, and additional biomarker tests.
A digital rectal exam (DRE) allows a physician to physically assess prostate size and texture. Multi-parametric MRI (mpMRI) has become an important adjunct when PSA is elevated, helping to identify suspicious regions before or instead of a systematic biopsy. Additional blood and urine-based biomarkers — such as the Prostate Health Index (PHI) and the 4Kscore — can help refine the probability of clinically significant cancer. No single test tells the complete story, which is why clinical context and physician judgment remain central to evaluation.
Where Medical Guidance Currently Stands
The debate over routine PSA screening has evolved considerably. The U.S. Preventive Services Task Force (USPSTF) recommends that men aged 55–69 make an individualized decision about PSA screening in consultation with their clinician, weighing the potential benefits against harms such as overdiagnosis and overtreatment. For men 70 and older, the Task Force advises against routine screening, given a less favorable benefit-harm balance at that age.
Other organizations, including the American Cancer Society and the American Urological Association, similarly emphasize shared decision-making and highlight that certain groups warrant earlier or more targeted conversations. Black men have roughly twice the incidence of prostate cancer compared with white men and a higher mortality rate; men with a first-degree relative diagnosed with prostate cancer before age 65 also face elevated risk. These individuals are generally encouraged to discuss screening starting at age 40 to 45.
~1 in 8
Lifetime prostate cancer risk for U.S. men
According to the American Cancer Society, approximately 1 in 8 men in the United States will be diagnosed with prostate cancer during their lifetime.
2x
Relative prostate cancer incidence in Black men
Black men in the U.S. are roughly twice as likely to be diagnosed with prostate cancer compared with white men, based on National Cancer Institute data.
~70%
Biopsies after elevated PSA that find no cancer
Research estimates suggest approximately two-thirds to three-quarters of men who undergo biopsy following an elevated PSA result do not have prostate cancer confirmed.
PSA screening exists in the broader landscape of men's preventive care. Routine screenings for men at different life stages cover far more than prostate health, and prioritizing that full picture matters. You may also find it useful to compare how colorectal cancer screening decisions are made, since similar shared decision-making principles apply.
Talk to Your Doctor Before Deciding on Screening
The decision to pursue PSA testing is not one-size-fits-all. Your age, family history, ethnicity, and personal preferences all influence whether screening is appropriate for you. Guidelines specifically recommend a documented conversation with your clinician so you understand both the potential benefits — detecting a significant cancer early — and the potential harms, including the risk of unnecessary biopsy or overtreatment of slow-growing disease. Do not skip this conversation based on assumptions in either direction.
This article is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health history and circumstances.